Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Contraceptive Technology Update

RSS  

Articles

  • Time to take aim at treating trichomoniasis

    While trichomoniasis is the most common curable sexually transmitted disease (STD) in the United States,1 reports of metronidazole-resistant trichomoniasis are increasing. New evidence indicates that tinidazole (Tindamax, Presutti Laboratories, Rolling Meadows, IL), recently introduced in the United States, is an effective therapy for metronidazole-resistant trichomoniasis and is well tolerated even at high doses.
  • Washington Watch: Health plans proposal poses access problems

    The Bush administration and conservative members of Congress are touting legislation to create Association Health Plans (AHPs) as one of their answers to the growing problem of the nations uninsured, which totaled 45 million in 2003. These plans would allow professional and trade associations to band together to use their heightened purchasing power to offer insurance coverage to their members.
  • Enter nominations now for clinician award

    Nominations are being accepted for the Inspirations in Womens Health contest, sponsored by the Washington, DC-based National Association of Nurse Practitioners in Womens Health (NPWH) and the St. Paul, MN-based 3M Pharmaceuticals. The contest recognizes nurse practitioners who go above and beyond the call of duty in the areas of womens reproductive and sexual health.
  • Update: Today contraceptive sponge returns to U.S. drugstore shelves

    Women who have been waiting for news of the Today contraceptive sponges re-emergence on U.S. market shelves can relax; the popular over-the-counter contraceptive should return to drugstore shelves this summer following the Food and Drug Administrations (FDAs) recent approval of the sponges manufacturing facility.
  • Injectable update: Subcutaneous form of Depo-Provera is approved

    The drug, approved by the Food and Drug Administration (FDA) in December, should be available on retail pharmacy shelves in mid-May, says An Phan, Pfizer corporate spokeswoman. Pricing has not been set yet on the drug, she adds.
  • New guideline details care of vulvodynia

    As you flip through the next patients chart, you review notes from several past visits, and all detail pain and burning on or around the vulva. According to the chart documentation, the patient states the vulvar area hurts most of the time, even when nothing is touching it.
  • EC in the ED: What is your state’s policy?

    When it comes to emergency contraception (EC), it is an accepted standard of care in your clinic. But when it comes to the emergency department (ED) at your local hospital, is it the same story?
  • STD Quarterly: Use the Internet to stem the spread of STD

    Facing an upward spike in its number of syphilis cases, the San Francisco Department of Public Health has spun its detection web in new directions, using a broad range of innovative Internet-based prevention interventions to stem the spread of the sexually transmitted disease (STD).
  • Bacterial vaginosis is focus of new research 

    A check of the next patients file indicates a repeat visit for treatment of bacterial vaginosis (BV). What is your next step?
  • Funding cuts threaten family planning source

    Is your clinic seeing more women without insurance coverage whose care is now funded by Medicaid? New statistics from the New York City-based Alan Guttmacher Institute (AGI) confirm your observations: Researchers estimate that in 2003, one in five women of reproductive age were uninsured, which signals a 10% increase since 2001.